Zealand Pharma petrelintide hits 10.7% weight loss at 42 weeks
Zealand Pharma has presented 42-week data from the Phase 2 ZUPREME-1 trial of petrelintide at the American Diabetes Association 2026 Scientific Sessions in New Orleans, showing that the once-weekly amylin analogue achieved up to 10.7% mean body-weight reduction from baseline compared with 1.7% for placebo — a statistically significant difference (p<0.001) that the Copenhagen-based company says supports advancement into Phase 3.
The trial enrolled 485 adults with a mean BMI of 36.7 kg/m² and body weight of 107.1 kg, randomised 5:1 across five petrelintide doses or placebo. The primary endpoint — percentage change in body weight at week 28 — was met across all five treatment arms. Between 88% and 98% of participants successfully escalated to their targeted maintenance dose.
Tolerability profile
Perhaps the most noteworthy finding for the competitive landscape is the tolerability data. Nausea, the most common gastrointestinal adverse event, was reported in 19.6% of petrelintide-treated participants against 6.2% for placebo — a gap that is notably narrower than that typically observed with GLP-1 receptor agonists at equivalent efficacy levels. Vomiting rates were actually lower on petrelintide (3.0%) than on placebo (6.2%), and only 1.5% of participants discontinued due to gastrointestinal adverse events.
David Kendall, chief medical officer of Zealand Pharma, said: "The double-digit weight reduction seen after 42 weeks of petrelintide treatment, along with rates of adverse events generally at or below the rates observed with placebo, highlight the potential of this novel amylin agonist as a future first-choice therapy for chronic weight management."
Beyond weight loss, treatment was associated with reductions in waist circumference of 7.9–10.8 cm (versus 4.3 cm with placebo), high-sensitivity C-reactive protein reductions of 17–41% (versus 6%), and triglyceride reductions of 12–21% (versus 9%), pointing to a broader cardiometabolic benefit profile that may become relevant for label negotiations with regulators.
Market context and competitive positioning
Petrelintide enters an obesity market currently dominated by GLP-1 receptor agonists — notably semaglutide (Novo Nordisk's Wegovy) and tirzepatide (Eli Lilly's Zepbound) — which have set a high bar for efficacy but face well-documented tolerability and adherence challenges in real-world use. The amylin class works through a distinct mechanism: amylin receptor activation restores sensitivity to leptin and induces satiety, offering a complementary or combinable mode of action rather than a direct competitive one.
That combinability is commercially significant. In 2025, Roche and Zealand Pharma entered an exclusive collaboration and licensing agreement to co-develop and co-commercialise petrelintide. In April 2026, the two companies formally endorsed advancement to Phase 3, with trial initiation planned for the second half of this year. Petrelintide's design — chemically stable with no fibrillation at neutral pH — was specifically engineered to enable co-formulation with other peptides, which would make a fixed-dose combination with a GLP-1 agent technically feasible.
The regulatory path will hinge on how Phase 3 is designed. Regulators will expect superiority or non-inferiority data against active comparators in at least some endpoints, and the FDA's obesity drug guidance emphasises durability of effect and cardiovascular outcomes. Full results from ZUPREME-1, including the week-51 safety follow-up, are expected to be published later in 2026, and will provide the more granular dataset that physicians and payers will require before forming firm views on petrelintide's place in therapy.